Form 4: Amprius Technologies Executive Jonathan Bornstein Executes Stock Options and Sells Shares Under 10b5-1 Plan

Jonathan Bornstein, President of Amprius Lab, exercised stock options and sold shares of Amprius Technologies under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 2, 2024, Jonathan Bornstein, President of Amprius Lab at Amprius Technologies, exercised stock options to acquire 125,983 shares of common stock at a price of $0.05 per share.
• Simultaneously, Bornstein sold 125,983 shares of common stock at an average price of $2.3782 per share, with prices ranging from $2.29 to $2.46.
• These transactions were executed automatically under a Rule 10b5-1 trading plan adopted on May 12, 2023.
• Following these transactions, Bornstein directly owns 558,930 shares of Amprius Technologies common stock, which includes 558,930 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reflects routine transactions under a pre-arranged plan. There's no indication of positive or negative implications for the company's performance.

Industry Context

This filing is a routine disclosure of insider transactions and doesn't necessarily indicate a change in the company's outlook or performance. It is common for executives to utilize 10b5-1 plans to diversify their holdings and avoid accusations of insider trading.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-arranged nature of the trades mitigates concerns about insider information.

Key Dates